TSH Biopharm Corporation Limited (TPEX:8432)

TSH Biopharm Corporation Company Description

TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan.

The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others.

It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid biopsy test designed for MRD detection and surveillance in stage I-III solid tumor patients; AlphaLiquid 100, a liquid biopsy test designed for patients with advanced solid cancers; AlphaLiquid HRR, AlphaSolid, and AlphaSolid HRR, a tissue biopsy test designed for patients with advanced solid cancers; UNITED which detects clinically-relevant genomic alterations in both DNA and RNA including microsatellite instability(MSI) and tumor mutational burden (TMB) biomarkers from FFPE tissue; Progsigna, a test for breast cancer test; and lung cancer panel.

The company was founded in 1999 and is headquartered in Taipei, Taiwan. TSH Biopharm Corporation Limited is a subsidiary of TTY Biopharm Company Limited.

TSH Biopharm Corporation Limited

Country	Taiwan
Founded	1999
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	76
CEO	Sze-Yuan Yang

Contact Details

Address: No. 3-1, Park Street Taipei, 11503 Taiwan
Phone	886 2 2655 8525
Website	tshbiopharm.com

Stock Details

Ticker Symbol	8432
Exchange	Taipei Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0008432006
SIC Code	2834

Key Executives

Name	Position
Sze-Yuan Yang	President
Jung-Liang Kao	Senior Division Director of Finance Division and Chief Financial Officer
Chen-Ju Kan	Senior Manager of the Accounting Department
Yu-Chung Wu	Senior Director of Sales
Chuan-Hsu Chen	Senior Director of Marketing
Hsin-Young Liu	Company Secretary